Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
August 04 2021 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced that Fred Guerard, PharmD, Chief Executive
Officer of Graybug Vision, will participate in a panel discussion
titled “Goldeneye” at the Wedbush PacGrow Healthcare Conference on
Wednesday, August 11, 2021 at 9:45 a.m. ET / 6:45 a.m. PT.
A live webcast of the panel will be available in the Investors
and Media section of the company’s website at
https://investors.graybug.vision/news-events/events-presentations.
Following the live webcast, a replay will be available at the same
location for 14 days.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a formulation of the pan-vascular
endothelial growth factor (VEGF) inhibitor, sunitinib malate
targeting a six-month or longer dosing regimen, inhibits multiple
neovascular pathways for the intravitreal treatment of retinal
diseases, including wet age-related macular degeneration. Graybug’s
other product candidates developed using its proprietary
technologies also include GB-401, an injectable sustained-release
formulation of a beta-adrenergic blocker prodrug, for primary
open-angle glaucoma, with a dosing regimen of once every six months
or longer, and GB-103, a longer-acting version of GB-102, designed
to maintain therapeutic drug levels in the retinal tissue for 12
months with a single injection. Founded in 2011 on the basis of
technology licensed from the Johns Hopkins University School of
Medicine, Graybug is headquartered in Redwood City, California. For
more information, please visit www.graybug.vision.
Investor ContactIR@graybug.vision(650)
487-2409 |
Media Contactmedia@graybug.vision(404)
384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024